. 2020 Jul 1;10:10753. doi: 10.1038/s41598-020-67485-6

Table 1.

Clinical Characteristics of patients with anti-NMDAR encephalitis.

Clinical features	Patients	Mean Std. deviation	P value
Sex
Female	58
Male	48
Age
Female_age		25.94 ± 1.64
Male_age		36.49 ± 2.3
Female_age vs male_age			P = 0.000^d
^a	Female 36; male 24
^b	Female 18; male 19
Symptom presentation
Behavioral changes
Female	49 (42 OS)
^a	35 (29 OS)
^b	10 (9 OS)
Male	30 (23 OS)
^a	15 (12 OS)
^b	11 (8 OS)
Seizures
Female	40 (14 OS; 22 FS)
^a	25 (4 OS; 12 FS)
^b	11 (6 OS; 8 FS)
Male	31 (19 OS; 17 FS)
^a	15 (8 OS; 9 FS)
^b	11 (8 OS; 7 FS)
Consciousness disturbance	32
Cognitive impairment	59
Language impairment	16
Focal limb weakness	3
Involuntary movement	16
Oral	10 (female^a)
Other	6
Number of symptoms
Female^c		4.06 ± 0.98 vs 1.88 ± 0.86	P = 0.000^d
Male^c		2.29 ± 1.0 vs 1.50 ± 0.79	P = 0.006^d
Female vs male^a		4.06 ± 0.98 vs 2.29 ± 1.0	P = 0.000^d
Female vs male^b		1.88 ± 0.86 vs 1.50 ± 0.79	P = 0.179^d
Imaging
Normal T2/FLAIR	74
Abnormal T2/FLAIR	28
Total ASL	23
Abnormal T2/Flair and focal high blood flow	9
Normal T2/Flair and focal high blood flow	13
EEG during peak stage		Median 19.5
Background activity (BA)
Normal	2 female; 2 male
Mild DPS	8 female; 17 male
Moderate DPS	19 female; 12 male
SDPS	13 female; 2 male
EDB	5 female^a; 1 male
Female^c			P = 0.000^e
Male^c			P = 0.461^e
Female vs male^a			P = 0.000^e
Female vs male^b			P = 0.657^e
CSF
White cells
Abnormal T2/FLAIR		89.63 ± 29.53
Normal T2/FLAIR		18.44 ± 7.42	P = 0.000^d
Abnormal T2/FLAIR vs normal
T2/FlAIR
Normal T2/FLAIR and focal high blood flow		4.9 ± 8.52
Protein
Abnormal T2/Flair		0.63 ± 0.06	P = 0.002^d
Normal T2/Flair		0.4 ± 0.03
Abnormal T2/Flair vs normal T2/Flair
ICU admission	9^a; 2^b
Tumor
Ovarian teratomas	4
Other	1
Therapy
First-line alone	103
First-line and second-line	3
With/without relapse
Female	3^a; 1^b
Male	4^a
mRS (follow-up from 12 to 50 months)	Median 19
0–1	37
≥ 2	53 (4 died)

Std. deviation standard deviation, mild DPS mild diffuse polymorphic slowing, moderate DPS moderate diffuse polymorphic slowing, SDPS severe diffuse polymorphic slowing, EDB extreme delta brush, ASL arterial spin labeling, CSF cerebrospinal fluid.

^aHigh CSF antibody titer (1:10 or 1:32).

^bLow CSF antibody titer (1:1 or 1:3.2).

^cLow CSF antibody titer (1:1 or 1:3.2) vs high CSF antibody titer (1:10 or 1:32).

^dIndependent-sample t test.

^eMann–Whitney U test. Onset denotes the number of patients with the clinical symptoms manifesting onset symptoms.